Nanopreparations to overcome multidrug resistance in cancer

被引:278
|
作者
Patel, Niravkumar R. [1 ]
Pattni, Bhushan S. [1 ]
Abouzeid, Abraham H. [1 ]
Torchilin, Vladimir P. [1 ]
机构
[1] Northeastern Univ, Ctr Pharmaceut Biotechnol & Nanomed, Boston, MA 02115 USA
关键词
Nanopreparations; Multidrug resistance; Spheroid culture; Combination therapy; CELL LUNG-CANCER; SURVIVIN SPLICE VARIANTS; POLYELECTROLYTE COMPLEX MICELLES; NANOPARTICULATE DELIVERY-SYSTEM; EPITHELIAL OVARIAN-CANCER; ATP-BINDING-CASSETTE; MDR1; GENE-EXPRESSION; DRUG-RESISTANCE; BREAST-CANCER; P-GLYCOPROTEIN;
D O I
10.1016/j.addr.2013.08.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multidrug resistance is the most widely exploited phenomenon by which cancer eludes chemotherapy. Broad variety of factors, ranging from the cellular ones, such as over-expression of efflux transporters, defective apoptotic machineries, and altered molecular targets, to the physiological factors such as higher interstitial fluid pressure, low extracellular pH, and formation of irregular tumor vasculature are responsible for multidrug resistance. A combination of various undesirable factors associated with biological surroundings together with poor solubility and instability of many potential therapeutic small & large molecules within the biological systems and systemic toxicity of chemotherapeutic agents has necessitated the need for nano-preparations to optimize drug delivery. The physiology of solid tumors presents numerous challenges for successful therapy. However, it also offers unique opportunities for the use of nanotechnology. Nanoparticles, up to 400 nm in size, have shown great promise for carrying, protecting and delivering potential therapeutic molecules with diverse physiological properties. In this review, various factors responsible for the MDR and the use of nanotechnology to overcome the MDR, the use of spheroid culture as well as the current technique of producing microtumor tissues in vitro are discussed in detail. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:1748 / 1762
页数:15
相关论文
共 50 条
  • [1] Nanomedicine to Overcome Cancer Multidrug Resistance
    Yang, Xi
    Yi, Cheng
    Luo, Na
    Gong, Changyang
    CURRENT DRUG METABOLISM, 2014, 15 (06) : 632 - 649
  • [2] Modulating ROS to overcome multidrug resistance in cancer
    Cui, Qingbin
    Wang, Jing-Quan
    Assaraf, Yehuda G.
    Ren, Liang
    Gupta, Pranav
    Wei, Liuya
    Ashby, Charles R., Jr.
    Yang, Dong-Hua
    Chen, Zhe-Sheng
    DRUG RESISTANCE UPDATES, 2018, 41 : 1 - 25
  • [3] Different strategies to overcome multidrug resistance in cancer
    Saraswathy, Manju
    Gong, Shaoqin
    BIOTECHNOLOGY ADVANCES, 2013, 31 (08) : 1397 - 1407
  • [4] Novel nanomedicines to overcome cancer multidrug resistance
    Su, Zhenwei
    Dong, Shaowei
    Zhao, Shan-Chao
    Liu, Kaisheng
    Tan, Yao
    Jiang, Xingyu
    Assaraf, Yehuda G.
    Qin, Bo
    Chen, Zhe-Sheng
    Zou, Chang
    DRUG RESISTANCE UPDATES, 2021, 58
  • [5] Overcome Multidrug Resistance in Colorectal Cancer by Natural Compounds
    Li, Yanxi
    Liu, Zhexian
    Guo, Xingqi
    Ma, Siping
    SCIENCE OF ADVANCED MATERIALS, 2020, 12 (07) : 933 - 949
  • [6] Natural Product Modulators to Overcome Multidrug Resistance In Cancer
    Cort, Aysegul
    Ozben, Tomris
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2015, 67 (03): : 411 - 423
  • [7] Nanocarriers for siRNA delivery to overcome cancer multidrug resistance
    MENG QingShuo
    YIN Qi
    LI YaPing
    Chinese Science Bulletin, 2013, 58 (33) : 4021 - 4030
  • [8] Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy
    Beretta, Giovanni L.
    Cavalieri, Francesca
    CURRENT MEDICINAL CHEMISTRY, 2016, 23 (01) : 3 - 22
  • [9] Nanocarriers for siRNA delivery to overcome cancer multidrug resistance
    MENG QingShuo
    YIN Qi
    LI YaPing
    Science Bulletin, 2013, (33) : 4021 - 4030
  • [10] Nanocarriers for siRNA delivery to overcome cancer multidrug resistance
    Meng QingShuo
    Yin Qi
    Li YaPing
    CHINESE SCIENCE BULLETIN, 2013, 58 (33): : 4021 - 4030